Development of ex vivo lung perfusion in lung transplantation

doi:10.3877/cma.j.issn.2095-8773.2015.04.003

Abstract

Abstract:

Developed rapidly in some European and American countries over the past decades, lung transplantation has been accepted as the best therapy that improves the survival and quantity of life for selected patients with end-stage lung or pulmonary vascular diseases. Ex vivo lung perfusion(EVLP) has emerged as a modern preservation technique that allows for more accurate lung assessment and also improvement of lung quality. Its application in high risk donor lungs has led to safe and substantial expansion of the donor pool. This paper reviews the growing development of EVLP application in lung transplantation.

Key words: Lung transplantation, Ex vivo lung perfusion, Research progress

Hang Zhang, Jian Cui. Development of ex vivo lung perfusion in lung transplantation[J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2015, 02(04): 222-226.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxbwkdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-8773.2015.04.003

https://zhxbwkdzzz.cma-cmc.com.cn/EN/Y2015/V02/I04/222

Figures/Tables 1

References 51

[1]	Yusen RD, Christie J, Edwards LB, et a1. The Registry of the International Society for Heart and Lung Transplantation: thirtieth adult lung and heart-lung transplant report-2013[J]．J Heart Lung Transplant，2013，32(10): 965-978.
[2]	Benden C, Edwards LB, Kucheryavaya AY, et a1. The Registry of the International Society for Heart and Lung Transplantation: sixteenth official pediatric lung and heart-lung transplantation report-2013[J]．J Heart Lung Transplant，2013，32 (10): 989-997.
[3]	Trulock EP, Christie JD, Edwards LB, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult lung and heart-lung transplantation report—2007[J]．J Heart Lung Transplant，2007，26(8)：782-795.
[4]	Gomez-de-Antonio D, Varela A. Non-heart-beating donation in Spain[J]．Gen Thorac Cardiovasc Surg，2011，59(1)：1-5.
[5]	Steen S, Sjoberg T, Pierre L, et al. Transplantation of lungs from a non-heart-beating donor[J]．Lancet，2001，357：825-829.
[6]	Cypel M, Sato M, Yildirim E, et al. Initial experience with lung donation after cardiocirculatory death in Canada[J]. J Heart Lung Transplant，2009，28：753-758.
[7]	Erasmus ME, Verschuuren EA, Nijkamp DM, et al. Lung transplantation from nonheparinized category III non-heart-beating donors. A single-centre report[J]. Transplantation，2010，89：452-457.
[8]	Love RB.Perspectives on lung transplantation and donation-after-determin-ation-of-cardiac-death donors[J]．Am J Transplant，2012，12：2271-2272.
[9]	Mason DP, Brown CR, Murthy SC, et al. Growing singlecenter experience with lung transplantation using donation after cardiac death[J]．Ann Thorac Surg, 2012，94：406-411；discussion 411-412.
[10]	De Oliveira NC, Osaki S, Maloney JD, et al. Lung transplantation with donation after cardiac death donors: long-term follow-up in a single center[J]．J Thorac Cardiovasc Surg，2010，139：1306-1315.
[11]	Levvey BJ, Harkess M, Hopkins P, et al. Excellent clinical outcomes from a national donation-after-determination-of-cardiac-death lung transplant collaborative[J]．Am J Transplant，2012，12：2406-2413.
[12]	Puri V, Scavuzzo M, Guthrie T, et al. Lung transplantation and donation after cardiac death: a single center experience[J]．Ann Thorac Surg，2009，88：1609-14; discussion 1614-1615.
[13]	Alessandrini F, D’Armini AM, Roberts CS, et al. When does the lung die? II. Ultrastructural evidence of pulmonary viability after "death" [J]．J Heart Lung Transplant，1994，13(5)：748-757.
[14]	D’Armini AM, Roberts CS, Griffith PK, et al. When does the lung die? I. Histochemical evidence of pulmonary viability after "death" [J]．J Heart Lung Transplant，1994，13(5)：741-747.
[15]	Egan TM. Non-heart-beating donors in thoracic transplantation[J]．J Heart Lung Transplant，2004，23(1)：3-10.
[16]	Van Raemdonck DE, Rega FR, Neyrinck AP, et al. Non-heart-beating donors[J]．Semin Thorac Cardiovasc Surg，2004，16(4)：309-321.
[17]	Egan TM, Lambert CJ Jr, Reddick R, et al. A strategy to increase the donor pool: use of cadaver lungs for transplantation[J]．J Ann Thorac Surg，1991，52(5)：1113-1120.
[18]	Ulicny KS Jr, Egan TM, Lambert CJ Jr，et al. Cadaver lung donors: effect of preharvest ventilation on graft function [J]．J Ann Thorac Surg，1993，55(5)：1185-1191.
[19]	Hammainen P. Re: use of extracorporeal membrane oxygenation as a bridge to primary lung transplant: 3 consecutive, successful cases and a review of the literature[J]．J Heart Lung Transplant，2008，27：1186.
[20]	Wallinder A, Ricksten SE, Hansson C, et al. Transplantation of initially rejected donor lungs after ex vivo lung perfusion[J]．J Thorac Cardiovasc Surg, 2012，144：1222-1228.
[21]	Ware LB, Wang Y, Fang X, et al. Assessment of lungs rejected for transplantation and implication for donor selection[J]．Lancet，2002，360(9333)：619-620.
[22]	Carrel A, Lindbergh CA.The culture of whole organs[J]．Science，1935，81: 621-623.
[23]	Jirsch DW, Fisk RL, Couves CM, et al. Ex vivo evaluation of stored lungs[J]．Ann Thorac Surg，1970，10：163-168.
[24]	Machuca TN, Cypel M. Ex vivo lung perfusion[J]．J Thorac Dise，2014，6(8)：1054-1062.
[25]	Steen S, Sjöberg T, Pierre L, et al. Transplantation of lungs from a non-heart-beating donor[J]．Lancet，2001，357：825-829.
[26]	Steen S, Ingemansson R, Eriksson L, et al. First human transplantation of a nonacceptable donor lung after reconditioning ex vivo[J]．Ann Thorac Surg, 2007，83：2191-194.
[27]	Cypel M, Yeung JC, Liu M, et al. Normothermic ex vivo lung perfusion in clinical lung transplantation[J]．N Engl J Med，2011，364：1431-1440.
[28]	Cypel M, Yeung JC, Machuca T, et al. Experience with the first 50 ex vivo lung perfusions in clinical transplantation[J]．J Thorac Cardiovasc Surg, 2012，144：1200-1206.
[29]	Cypel M, Rubacha M, Yeung J, et al. Normothermic ex vivo perfusion prevents lung injury compared to extended cold preservation for transplantation[J]．Am J Transplant，2009，9：2262-2269.
[30]	Cypel M, Yeung JC, Hirayama S, et al. Technique for prolonged normothermic ex vivo lung perfusion[J]．J Heart Lung Transplant，2008，27：1319-1325.
[31]	Yeung JC, Cypel M, Waddell TK, et al. Update on donor assessment, resuscitation, and acceptance criteria, including novel techniques-non-heart-beating donor lung retrieval and ex vivo donor lung perfusion[J]. Thorac Surg Clin, 2009，19：261-274.
[32]	Medeiros IL, Pêgo-Fernandes PM, Mariani AW, et al. Comparison of lung preservation solutions in human lungs using an ex vivo lung perfusion experimental model[J]．Clinics (Sao Paulo), 2012，67: 1101-1106.
[33]	Soares PR, Braga KA, Nepomuceno NA, et al. Comparison between Perfadex and locally manufactured lowpotassium dextran solution for pulmonary preservation in an ex vivo isolated lung perfusion model[J]．Transplant Proc，2011，43: 84-88.
[34]	Menezes AQ, Pêgo-Fernandes PM, Cardoso PF, et al. Comparison of celsior and perfadex lung preservation solutions in rat lungs subjected to 6 and 12 hours of ischemia using an ex-vivo lung perfusion system[J]．Clinics (Sao Paulo), 2012，67: 1309-1314.
[35]	Steen S, Ingemansson R, Eriksson L, et al. First human transplantation of a nonacceptable donor lung after reconditioning ex vivo[J]. Ann Thorac Surg，2007, 83：2191-2194.
[36]	Erasmus ME, Fernhout MH, Elstrodt JM, et al. Normothermic ex vivo lung perfusion of nonheart-beating donor lungs in pigs: from pretransplant function analysis towards a 6-h machine preservation[J]．Transpl Int，2006，19：589-593.
[37]	Cypel M, Yeung JC, Hirayama S, et al. Technique for prolonged normothermic ex vivo lung perfusion[J]. J Heart Lung Transplant，2008，27：1319-1325.
[38]	Steen S, Ingemansson R, Eriksson L, et al. First human transplantation of a nonacceptable donor lung after reconditioning ex vivo[J]．Ann Thorac Surg, 2007，83：2191-2194.
[39]	Lindstedt S, Hlebowicz J, Koul B, et al. Comparative outcome of double lung transplantation using conventional donor lungs and non-acceptable donor lungs reconditioned ex vivo[J]．Interact Cardiovasc Thorac Surg，2011，12: 162-165.
[40]	Aigner C, Slama A, Hötzenecker K, et al. Clinical ex vivo lung perfusion--pushing the limits[J]．Am J Transplant，2012，12: 1839-1847.
[41]	Zych B, Popov AF, Stavri G, et al. Early outcomes of bilateral sequential single lung transplantation after ex-vivo lung evaluation and reconditioning[J]．J Heart Lung Transplant，2012，31: 274-281.
[42]	Wallinder A, Ricksten SE, Silverborn M, et al. Early results in transplantation of initially rejected donor lungs after ex vivo lung perfusion: a case-control study[J]. Eur J Cardiothorac Surg, 2014，45: 40-44; discussion 44-45.
[43]	Warnecke G, Moradiellos J, Tudorache I, et al. Normothermic perfusion of donor lungs for preservation and assessment with the organ care system lung before bilateral transplant: a pilot study of 12 patients[J]．Lancet，2012，380: 1851-1858.
[44]	Gomez-de-Antonio D, Campo-Canareral JL, Crowley S, et al. Clinial lung transplantion from uncontraled non-heart-beating donors revisited[J]．J Heart Lung Transplant，2012，31(4)：349-353.
[45]	de Antonio DG, Marcos R, Laporta R, et al. Results of clinical lung transplant from uncontrolled non-heart beating donors[J]．J Heart Lung Transplant, 2007，26：529-534.
[46]	Moradiellos FJ, Naranjo JM, Córdoba M, et al. Clinical lung transplantation after ex vivo evaluation of uncontrolled non heart-beating donors lungs: initial experience[J]．J Heart Lung Transplant，2011，30：S38.
[47]	Egan T, Blackwell J, Forrest L, et al. Evaluation of human lungs from category 1 non-heart-beating donors (NHBDs) with ex-vivo lung perfusion (EVLP) in the U．S.[J]. Chest，2014，145：635A.
[48]	Ware LB, Fang X, Wang Y, et al. Selected contribution: mechanisms that may stimulate the resolution of alveolar edema in the transplanted human lung[J]．J Appl Physiol，2002，93(5)：1869-1874.
[49]	Cypel M, Yeung J, Hirayama S, et al. Technique for prolonged normothermic ex vivo lung perfusion[J]. J Heart Lung Transplant，2008，27(12): 1319-25.
[50]	Yeung JC, Wagnetz D, Cypel M, et al. Ex vivo adenoviral vector gene delivery results in decreased vector-associated inflammation pre- and post-lung transplantation in the pig[J]．Mol Ther, 2012，20: 1204-1211.
[51]	Emaminia A, Lapar DJ, Zhao Y, et al. Adenosine A_2A agonist improves lung function during ex vivo lung perfusion[J]．Ann Thorac Surg，2011，92(5): 1840-1846.

指标		多伦多系统	Lund系统	OCS系统
灌注量		40%心输出量(1 h)	100%心输出量(1h)	2.5 L(15～30 min)
开始流速(ml/min)		150	100	200
肺动脉压(mmHg)		<15	<20	<20
左心房压(mmHg)		3～5	0	0
灌注液		2 L Steen液	2 L Steen液＋红细胞(压积10%)	1.5 L Steen液＋红细胞(压积20%)
通气模式		容控	容控	容控
潮气量(ml/kg)		07	05	06
频率(次/min)		07	20	10
PEEP(cmH₂O)		05	05	05
吸入氧浓度(%)		21	50	21
温度(℃)		?	?	?
?	通气开始	32	32	32
?	灌注开始	25	25	32
?	评估开始	37	37	37
灌注时间(h)		12	02	5(3～10)

指标		多伦多系统	Lund系统	OCS系统
灌注量		40%心输出量(1 h)	100%心输出量(1h)	2.5 L(15～30 min)
开始流速(ml/min)		150	100	200
肺动脉压(mmHg)		<15	<20	<20
左心房压(mmHg)		3～5	0	0
灌注液		2 L Steen液	2 L Steen液＋红细胞(压积10%)	1.5 L Steen液＋红细胞(压积20%)
通气模式		容控	容控	容控
潮气量(ml/kg)		07	05	06
频率(次/min)		07	20	10
PEEP(cmH₂O)		05	05	05
吸入氧浓度(%)		21	50	21
温度(℃)		?	?	?
?	通气开始	32	32	32
?	灌注开始	25	25	32
?	评估开始	37	37	37
灌注时间(h)		12	02	5(3～10)

Please choose a citation manager

Content to export